Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.Nature Communications|April 26, 2017
Exploiting induced pluripotent stem cell-derived macrophages to unravel host factors influencing Chlamydia trachomatis pathogenesisAmy T Y Yeung, Christine Hale, Amy H Lee, et al.Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.Genome Biology|January 22, 2021
Minimal genome-wide human CRISPR-Cas9 libraryEmanuel Gonçalves, Mark Thomas, Fiona M Behan, et al.Life Science Alliance|February 28, 2023
Regulatory de novo mutations underlying intellectual disabilityMatias G De Vas, Fanny Boulet, Shweta S Joshi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.Journal of Medical Genetics|December 5, 2023
Short-read whole genome sequencing identifies causative variants in most individuals with previously unexplained aniridiaHildegard Nikki Hall, David Parry, Mihail Halachev, et al.Human Mutation|February 20, 2004
The role of cathepsin C in Papillon-Lefèvre syndrome, prepubertal periodontitis, and aggressive periodontitisChelsee Hewitt, Derek McCormick, Gerry Linden, et al.Pageof 14